Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy
Tóm tắt
Although imatinib has shown high activity in the majority of patients with advanced gastrointestinal stromal tumors (GIST), it has become clear that secondary resistance appears during chronic therapy. The aim of this study was to retrospectively analyze the safety and prognostic effects of surgical interventions for focal progression during imatinib treatment. Between January 2002 and May 2005, 16 patients who had focal lesions of secondary-resistant GIST to imatinib treatment (male/female, 12 : 4; median age, 62 years) underwent surgical interventions such as resection, radiofrequency ablation, and their combination. Postoperative complications, including liver abscess, bile leak, wound infection, and ileus were mostly mild, and the patients recovered with conservative therapy. There was no hospital death. The median time to progression (TTP) of all patients was 5.5 months, and only one patient died of the disease; the others are alive after a median follow up of 12.4 months. Patients with complete resections of resistant lesions (n = 7) showed significantly better median TTP than those with incomplete resections (n = 9; P = 0.014). The impact of curability on focal lesions with secondary resistance was mainly significant in patients with tumors of stomach origin (P = 0.013), and a smaller number (P = 0.014) and smaller size (P = 0.018) of resistant lesions. Overall survival was 100% at 1 year and 75% at 2 years. Our study indicates that surgical interventions in patients with GIST resistant to imatinib therapy are efficacious when complete resections are performed, when the lesions are of gastric origin, when the number of lesions is lower, and when the lesions are a smaller size.
Tài liệu tham khảo
T Nishida S Hirota (2000) ArticleTitleBiological and clinical review of stromal tumors in the gastrointestinal tract Histol Histopathol 15 1293–1301 Occurrence Handle11005253 Occurrence Handle1:STN:280:DC%2BD3cvltValuw%3D%3D
RP DeMatteo MC Heinrich WM El-Rifai et al. (2002) ArticleTitleClinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 466–477 Occurrence Handle12094371 Occurrence Handle10.1053/hupa.2002.124122 Occurrence Handle1:CAS:528:DC%2BD38XlslCls7o%3D
RP DeMatteo JJ Lewis D Leung et al. (2002) ArticleTitleTwo hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival Ann Surg 231 51–58 Occurrence Handle10.1097/00000658-200001000-00008
PJ Roberts B Eisenberg (2001) ArticleTitleClinical presentation of gastrointestinal stromal tumors and treatment of operative disease Eur J Cancer 38 S37–38 Occurrence Handle10.1016/S0959-8049(02)80601-3
AT Van Oosterom I Judson J Verweij et al. (2001) ArticleTitleSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study Lancet 358 1421–1423 Occurrence Handle11705489 Occurrence Handle10.1016/S0140-6736(01)06535-7 Occurrence Handle1:CAS:528:DC%2BD3MXot1Ojtb0%3D
H Joensuu PJ Roberts M Sarlomo-Rikala et al. (2001) ArticleTitleEffect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052–1056 Occurrence Handle11287975 Occurrence Handle10.1056/NEJM200104053441404 Occurrence Handle1:STN:280:DC%2BD3M3gvVekuw%3D%3D
GD Demetri M von Mehren CD Blanke et al. (2002) ArticleTitleEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472–480 Occurrence Handle12181401 Occurrence Handle10.1056/NEJMoa020461 Occurrence Handle1:CAS:528:DC%2BD38XmtV2nt7s%3D
J Verweji PG Casali J Zalcberg et al. (2004) ArticleTitleProgression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial Lancet 364 1127–1134 Occurrence Handle10.1016/S0140-6736(04)17098-0
C Rankin M von Mehren C Blanke et al. (2004) ArticleTitleContinued prolongation of survival by imatinib with metastatic GIST. Update of results from North American Intergroup phase III study S0033 (abstract) Proc Am Soc Clin Oncol 23 815
GD Demetri R Benjamin CD Blanke et al. (2004) ArticleTitleOptimal management of patients with gastrointestinal stromal tumor (GIST) – expansion and update of NCCN Clinical Practice Guidelines J Natl Compr Canc Netw 2 S1–S26
JY Blay S Bonvalot P Casali et al. (2005) ArticleTitleConsensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20–21 March 2004, under the auspices of ESMO Ann Oncol 16 566–578 Occurrence Handle15781488 Occurrence Handle10.1093/annonc/mdi127
JR Zalcberg J Verweji PG Casali et al. (2004) ArticleTitleOutcome of patients with advanced gastro-intestinal stromal tumours (GIST) crossing over to a daily imatinib dose of 800 mg (HD) after progression on 400 mg (LD) – an international, intergroup study of EORTC, ISG and AGITG (abstract) Proc Am Soc Clin Oncol 23 815
GD Demetri AT van Oosterom M Blackstein et al. (2005) ArticleTitlePhase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST (abstract) Proc Am Soc Clin Oncol 23 308
RG Maki JA Fletcher MC Heinrich et al. (2005) ArticleTitleSU11248 in patients with imatinib-resistant GIST: results from a continuation trial (abstract) Proc Am Soc Clin Oncol 23 818
S Bauer JT Hartmann M de Wit et al. (2005) ArticleTitleResection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib Int J Cancer 117 316–325 Occurrence Handle15900603 Occurrence Handle10.1002/ijc.21164 Occurrence Handle1:CAS:528:DC%2BD2MXhtVygsrfK
A Gronchi M Fiore R Bertulli et al. (2005) ArticleTitleSurgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST) (abstract) Proc Am Soc Clin Oncol 23 825
P Rutkowski Z Nowecki P Nyckowski et al. (2005) ArticleTitleSurgical treatment of patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy (abstract) Proc Am Soc Clin Oncol 23 825
P Hohenberger C Langer S Pistorius et al. (2006) ArticleTitleIndication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST) (abstract) Proc Am Soc Clin Oncol 24 520s
LL Chen M Sabripour RHI Andtbacka et al. (2005) ArticleTitleImatinib resistance in gastrointestinal stromal tumors Curr Oncol Rep 7 293–299 Occurrence Handle15946589 Occurrence Handle10.1007/s11912-005-0053-6 Occurrence Handle1:CAS:528:DC%2BD28XktVarsw%3D%3D
NG Eng-hen RE Pollock MF Munsell et al. (1992) ArticleTitlePrognostic factors influencing survival in gastrointestinal leiomyosarcomas Ann Surg 215 68–77